Revive Therapeutics Ltd.
- Country
- π¨π¦Canada
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.revivethera.com
Clinical Trials
3
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)β’ Click on a phase to view related trials
Bucillamine in Treatment of Patients With COVID-19
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- Revive Therapeutics, Ltd.
- Target Recruit Count
- 713
- Registration Number
- NCT04504734
- Locations
- πΊπΈ
Cullman Clinical Trials, Cullman, Alabama, United States
πΊπΈAvant Research Associates, LLC, Huntsville, Alabama, United States
πΊπΈWest Valley Research Clinic, Phoenix, Arizona, United States
Bucillamine Phase 2 Trial in Patients With Cystinuria
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Revive Therapeutics, Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02942420
- Locations
- πΊπΈ
University of Alabama - Department of Urology, Birmingham, Alabama, United States
πΊπΈMassachusette General Hospital, Boston, Massachusetts, United States
πΊπΈNew York University School of Medicine, New York, New York, United States
Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout
- First Posted Date
- 2015-01-05
- Last Posted Date
- 2016-10-05
- Lead Sponsor
- Revive Therapeutics, Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT02330796
- Locations
- πΊπΈ
West Coast Research, San Roman, California, United States
πΊπΈTexas Physicians Research Medical Group, Arlington, Texas, United States
πΊπΈSun Research Institute, San Antonio, Texas, United States